{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:13:34Z","timestamp":1793654014221,"version":"4.5.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jhep.2022.09.027","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T18:11:59Z","timestamp":1667067119000},"page":"513-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-7955","authenticated-orcid":false,"given":"Edward J.","family":"Gane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9626-2600","authenticated-orcid":false,"given":"P. Rod","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5952-3813","authenticated-orcid":false,"given":"Jeffrey J.","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2746-4422","authenticated-orcid":false,"given":"Nicholas","family":"van Buuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-6179","authenticated-orcid":false,"given":"Simon P.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna K.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamasundaran","family":"Kottilil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-9220","authenticated-orcid":false,"given":"Lydia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.09.027_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic potential of TLR8 agonist GS-9688 (Selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.09.027_bib2","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.0c00100","article-title":"Discovery of GS-9688 (Selgantolimod) as a potent and selective oral Toll-like receptor 8 Agonist for the treatment of chronic hepatitis B","volume":"63","author":"Mackman","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2022.09.027_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nri3446","article-title":"The history of Toll-like receptors - redefining innate immunity","volume":"13","author":"O'Neill","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2022.09.027_bib4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/cmi.2012.38","article-title":"TLR8: the forgotten relative revindicated","volume":"9","author":"Cervantes","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2022.09.027_bib5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","article-title":"Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8","volume":"174","author":"Gorden","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2022.09.027_bib6","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1016\/j.vaccine.2010.06.117","article-title":"TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity","volume":"28","author":"Du","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2022.09.027_bib7","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1084\/jem.20052433","article-title":"Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates","volume":"203","author":"Wille-Reece","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jhep.2022.09.027_bib8","unstructured":"World Health Organization. Hepatitis B Key Facts. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed February 18,\u00a02021."},{"key":"10.1016\/j.jhep.2022.09.027_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2022.09.027_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jhep.2022.09.027_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2022.09.027_bib12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.09.027_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.09.027_bib14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.09.027_bib15","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.09.027_bib16","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.09.027_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"6","author":"Peppa","year":"2010","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jhep.2022.09.027_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3851\/IMP3363","article-title":"Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects","volume":"25","author":"Reyes","year":"2020","journal-title":"Antivir Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.09.027_bib19","first-page":"437A","article-title":"Characterization of cytokine response to toll-like receptor 8 agonist selgantolimod (SLGN) in viremic and virally suppressed chronic hepatitis B (CHB) patients","volume":"72","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.09.027_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B","volume":"73","author":"Daffis","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.09.027_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2022.09.027_bib22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/hep.31795","article-title":"Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822031488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822031488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:56Z","timestamp":1759175276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822031488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0168827822031488"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.09.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}